POS0114 LUPUS NEPHRITIS AND RESPONSE TO TREATMENT IN LATIN AMERICA
Authors: R. Quintana, R. Nieto, D. C. Fernández Ávila, R. Serrano, G. Harvey, L. Hernández, K. Roberts, M. Scolnik, C. Funes Soaje, P. Alba, V. Saurit, M. A. García, G. Berbotto, V. Bellomio, W. Patiño Grageda, G. Gómez, C. Pisoni, A. Malvar, V. Juarez, N. A. Da Silva, O. A. Monticielo, H. A. Mariz, F. Machado Ribeiro, E. F. Borba, L. Parente, E. Torres, O. Neira, L. Massardo, G. Aroca Martínez, C. A. Cañas Davila, G. Quintana López, C. E. Toro-Gutierrez, M. Moreno Alvarez, A. Zúñiga, M. A. Saavedra Salinas, M. Portela Hernandez, H. Fragoso Loyo, L. Silveira, I. García De La Torre, C. Abud Mendoza, M. Fonseca Hernández, J. A. Esquivel-Valerio, I. Acosta Colmán, J. Losanto, C. Mora Trujillo, K. Zuñiga Corrales, R. Muñoz Louis, M. Rebella, Á. Danza, M. F. Ugarte-Gil, G. S. Alarcón, U. Sbarigia, F. Zazzetti, A. Orillion, G. Pons-Estel, B. Pons-Estel
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Lupus nephritis (LN) is one of the most common, serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Data on treatment response among Latin American patients with LN remain limited. <h3>Objectives:</h3> To describe the rate of treatment response at 12 months in a cohort of SLE patients with active LN. <h3>Methods:</h3> GLADEL 2.0 is an observational prevalent and incident cohort. Forty-four centers from 10 Latin-American countries enrolled patients ≥18 years old who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. Patients were categorized into 4 subsets according to the presence of LN. For this analysis, patients in Group III (prevalent and active LN) and IV (incident LN, onset &lt;3 months with renal biopsy) and sufficient follow-up data at 12 months were included. Baseline demographics, clinical manifestations, disease activity (SLEDAI-2k) and SLICC/ACR Damage Index (SDI) and LN treatments were examined. Partial and complete response according to EULAR/KDIGO were examined at 12 months: Complete Response Criteria (CRC): proteinuria &lt;0.5 g/g measured as the urine protein to creatinine ratio (UPCR) from a 24-h urine collection; Partial Response Criteria (PRC): ≥50% reduction in UPCR from a 24-h urine collection and No Response (NR): &lt;50% reduction in proteinuria. <h3>Results:</h3> One-thousand eighty-one patients were enrolled in GLADEL 2.0 with 364 patients included in this analysis: 195 (53.5%) in group III and 169 (46.4%) in group IV. At the 12-month follow-up, 13/364 (3.5%) patients had died, 14/364 (3.8%) had been lost to follow-up and 28/364 (7.6%) had incomplete data; therefore, the calculation of renal response was carried out in the remaining 309 patients. Table 1 describes the characteristics of patients with LN. Table 2 shows that patients who achieved renal response (complete or partial) had a shorter disease duration, greater use of pulse corticosteroids and IV cyclophosphamide, a lower chronicity index and all belonged to the LN incident group. When comparing complete vs partial response, patients who achieved complete response had lower baseline proteinuria and creatinine values, belonged to histological Class III and had lower SLEDAI. <h3>Conclusion:</h3> Renal response was achieved in 64% of patients having their first episode of LN, with lower chronicity rates in the biopsy and a lower SLEDAI. Pulsed corticosteroids and IV cyclophosphamide continue to be the options chosen by treating physicians. More data in the follow-up will allow us to evaluate the persistence of this response over time and what factors may influence it. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Medical writing support was provided by Panita Maturavongsadit, PhD, of Lumanity Communications Inc., and was funded by Janssen Global Services, LLC. <h3>Disclosure of Interests:</h3> Rosana Quintana: None declared, Romina Nieto: None declared, Diana Carolina Fernández Ávila: None declared, Rosa Serrano: None declared, Guillermina Harvey: None declared, Lucia Hernández: None declared, Karen Roberts: None declared, Marina Scolnik Speaker fees/advisory: GSK, Astrazeneca, Janssen, Roche, Pfizer, Grants: GSK, Astrazeneca, Janssen, Roche, Pfizer, Carmen Funes Soaje: None declared, Paula Alba: None declared, Verónica Saurit: None declared, Mercedes Argentina García: None declared, Guillermo Berbotto: None declared, Verónica Bellomio: None declared, Wilfredo Patiño Grageda: None declared, Graciela Gómez: None declared, Cecilia Pisoni: None declared, Ana Malvar: None declared, Vicente Juarez: None declared, Nílzio A. da Silva: None declared, Odirlei André Monticielo: None declared, Henrique Ataide Mariz: None declared, Francinne Machado Ribeiro: None declared, Eduardo F. Borba: None declared, Luciana Parente Speaker GSK, astrazeneca, Edgard Torres: None declared, Oscar Neira: None declared, Loreto Massardo: None declared, Gustavo Aroca Martínez: None declared, Carlos A. Cañas Davila: None declared, Gerardo Quintana López: None declared, Carlos Enrique Toro-Gutierrez: None declared, Mario Moreno Alvarez: None declared, Andres Zúñiga: None declared, Miguel A. Saavedra Salinas: None declared, Margarita Portela Hernandez: None declared, Hilda Fragoso Loyo: None declared, Luis Silveira: None declared, Ignacio García De La Torre: None declared, Carlos Abud Mendoza: None declared, Marcos Fonseca Hernández: None declared, Jorge Antonio Esquivel-Valerio: None declared, Isabel Acosta Colmán: None declared, Jhonatan Losanto: None declared, Claudia Mora Trujillo: None declared, Katiuska Zuñiga Corrales: None declared, Roberto Muñoz Louis: None declared, Martin Rebella: None declared, Álvaro Danza: None declared, Manuel F. Ugarte-Gil Speaker: GSK and Aztra-Zeneca, Advisory boards: Aztra-Zeneca and Ferrer, Grant support: Janssen, Graciela S. Alarcón: None declared, Urbano Sbarigia Johnson &amp; Johnson, Johnson &amp; Johnson, Federico Zazzetti Johnson &amp; Johnson, Johnson &amp; Johnson, Ashley Orillion Johnson &amp; Johnson, Johnson &amp; Johnson, Guillermo Pons-Estel Speaker and/or advisor: AstraZeneca, GSK, Janssen, Bernardo Pons-Estel Speaker and/or advisor and/or steering committee for the following companies: AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, Grants, consulting fees: AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics.